Moffitt Cancer Center Receives $22.4 Million Grant to Study Deadly Leptomeningeal Disease

Breakthrough Research for Rare Cancer Condition

• 🔬 Moffitt Cancer Center has been awarded a significant $22.4 million federal grant to research a rare and often deadly condition.
• 🎯 This condition, known as leptomeningeal disease (LMD), specifically affects patients who are already battling cancer.

Patient Success Story: Heather Curley

• 🌟 Heather Curley, a patient diagnosed with metastatic stage 4 breast cancer, has defied the odds after enrolling in a clinical trial for LMD.
• ⏳ Typically, patients with this disease have only a few months to live, but Heather has lived for 26 months thanks to the trial.
• 💡 Her journey highlights the critical need for research and the hope that clinical trials offer to those with rare conditions.

Understanding Leptomeningeal Disease (LMD)

• 🧠 LMD occurs when the primary cancer spreads to the spinal cord fluid that bathes the brain.
• ⚠️ Dr. Peter Foresight notes that patients with LMD are often young, and understanding the reasons behind this is a key focus of the research.
• 🚀 The research aims to understand why this condition affects patients and to find effective treatments.

Future of LMD Research at Moffitt

• 💰 The $22.4 million grant will fund research and two clinical trials over the next four to six years.
• 🤝 Dr. Foresight's lab will lead this groundbreaking work, with a portion of the grant also going to Kent State.
• ✅ The overarching goal is to find a cure for LMD, driven by the belief that it is a solvable problem.

Hope and Awareness for LMD Patients

• 🌱 Heather Curley is now dedicated to raising awareness about LMD, encouraging others with the condition to know that hope exists.
• 💖 She emphasizes the importance of living life to the fullest and seeing generations of women overcome significant health challenges.